Brookstone Capital Management Buys 20,307 Shares of Boston Scientific Co. (NYSE:BSX)

Brookstone Capital Management lifted its holdings in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 23.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 105,860 shares of the medical equipment provider's stock after purchasing an additional 20,307 shares during the period. Brookstone Capital Management's holdings in Boston Scientific were worth $9,455,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the stock. State Street Corp lifted its stake in shares of Boston Scientific by 2.3% during the 3rd quarter. State Street Corp now owns 62,846,328 shares of the medical equipment provider's stock worth $5,266,522,000 after purchasing an additional 1,389,172 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Boston Scientific by 2.2% during the 3rd quarter. Wellington Management Group LLP now owns 32,820,828 shares of the medical equipment provider's stock valued at $2,750,385,000 after acquiring an additional 718,515 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Boston Scientific by 1.7% in the third quarter. Geode Capital Management LLC now owns 29,584,841 shares of the medical equipment provider's stock worth $2,469,607,000 after buying an additional 480,729 shares during the period. Legal & General Group Plc grew its position in Boston Scientific by 2.7% in the second quarter. Legal & General Group Plc now owns 13,922,773 shares of the medical equipment provider's stock valued at $1,072,195,000 after acquiring an additional 360,793 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in Boston Scientific by 0.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 8,018,377 shares of the medical equipment provider's stock valued at $671,940,000 after purchasing an additional 64,720 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Stock Up 1.0 %

Shares of NYSE BSX traded up $0.93 during mid-day trading on Tuesday, reaching $95.54. The company had a trading volume of 5,415,708 shares, compared to its average volume of 5,366,117. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48. The company has a market capitalization of $140.81 billion, a price-to-earnings ratio of 78.96, a PEG ratio of 2.67 and a beta of 0.80. The stock has a fifty day moving average of $90.16 and a two-hundred day moving average of $84.02. Boston Scientific Co. has a 12-month low of $59.61 and a 12-month high of $97.13.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, beating analysts' consensus estimates of $0.59 by $0.04. The business had revenue of $4.21 billion for the quarter, compared to the consensus estimate of $4.04 billion. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. Boston Scientific's revenue for the quarter was up 19.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.50 EPS. As a group, equities research analysts expect that Boston Scientific Co. will post 2.46 EPS for the current year.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig sold 4,877 shares of the stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $91.63, for a total value of $446,879.51. Following the completion of the sale, the director now directly owns 39,398 shares of the company's stock, valued at $3,610,038.74. This represents a 11.02 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP John Bradley Sorenson sold 4,119 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $90.02, for a total transaction of $370,792.38. Following the completion of the sale, the executive vice president now owns 35,319 shares of the company's stock, valued at approximately $3,179,416.38. The trade was a 10.44 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 29,989 shares of company stock worth $2,702,261. 0.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

BSX has been the topic of a number of recent analyst reports. Sanford C. Bernstein upped their target price on Boston Scientific from $92.00 to $100.00 and gave the company an "outperform" rating in a research report on Thursday, October 24th. Citigroup upped their price target on shares of Boston Scientific from $98.00 to $107.00 and gave the company a "buy" rating in a report on Wednesday, December 11th. BTIG Research raised their price objective on shares of Boston Scientific from $84.00 to $93.00 and gave the stock a "buy" rating in a report on Monday, October 14th. JPMorgan Chase & Co. upped their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the company an "overweight" rating in a research note on Monday, December 16th. Finally, Truist Financial lifted their price target on Boston Scientific from $100.00 to $110.00 and gave the stock a "buy" rating in a research note on Wednesday, December 18th. Three investment analysts have rated the stock with a hold rating, twenty have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $97.26.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.